Indole Analogs as Novel Treatments for OCD

吲哚类似物作为强迫症的新疗法

• 批准号: 7217884
• 负责人: HOWARD P SARD
• 金额: $ 46.96万
• 依托单位: ORGANIX, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7217884
• 关键词: Indole; Analogs; Novel; Treatments; OCD

DESCRIPTION (provided by applicant): Obsessive Compulsive Disorder (OCD) is a serious mental illness that affects millions of people throughout the world. Existing therapies for OCD show limited efficacy, can possess troubling side effects, and often require long-term treatment. Discovery of a new treatment for OCD would have considerable scientific and commercial value. One approach to pharmacotherapy for OCD is the development of selective 5-HT2C receptor agonists, which was the focus of our Phase One work. In Phase Two, we propose to optimize and further develop these leads through a Structure-Activity Relationship (SAR) program of synthesis and biological evaluation. From this project we specifically aim to discover one or more indole analogs showing efficacy in our animal model for OCD that is comparable to approved medications. Such leads will also display favorable drug-like properties. The long term goal of this project is to discover a new, improved pharmaceutical agent for treatment of OCD that can be licensed and developed for ultimate market approval.

描述（由申请人提供）： 强迫症 (OCD) 是一种严重的精神疾病，影响全世界数百万人。现有的强迫症疗法效果有限，可能具有令人不安的副作用，并且通常需要长期治疗。发现强迫症的新疗法将具有相当大的科学和商业价值。强迫症药物治疗的一种方法是开发选择性 5-HT2C 受体激动剂，这是我们第一阶段工作的重点。在第二阶段，我们建议通过合成和生物学评估的结构-活性关系（SAR）计划来优化和进一步开发这些先导化合物。从这个项目中，我们的具体目标是发现一种或多种吲哚类似物，在我们的强迫症动物模型中显示出与批准的药物相当的功效。此类先导化合物还将显示出有利的药物样特性。该项目的长期目标是发现一种新的、改进的用于治疗强迫症的药剂，该药剂可以获得许可和开发以最终获得市场批准。